Confronting a metabolic epidemic: understanding liver health and how to prevent, diagnose, and manage liver disease | Julia Wattacheril, M.D., M.P.H.

Peter Attia

May 20, 2024

Episode description

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter’s Weekly Newsletter

Julia Wattacheril is a physician scientist and director of the Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) program at Columbia University Irving Medical Center. In this episode, Julia delves deep into the complex world of liver health, beginning with a foundational overview of liver physiology. She provides an in-depth look at how alcohol impacts liver function, breaking down the metabolism of ethanol and its detrimental effects. Julia then shifts the focus to understanding liver function tests and optimal enzyme levels, providing a detailed explanation of AST and ALT and elucidating why fluctuations in these levels may or may not be concerning. She provides a primer on the four major stages of liver disease, discussing risk and emphasizing the importance of early diagnosis. Julia highlights the role of liver disease in increasing the risk of cancer and cardiovascular disease and covers in detail the various strategies for diagnosing, treating, and preventing the progression of liver disease.

We discuss:

  • Julia’s training, the importance of liver health, and the challenges and innovations of hepatology [3:15];

  • The complex and crucial functionality of the liver, its four most essential functions, and more [8:45];

  • Liver injuries: historical and evolving understanding of causal factors, and the progression to liver diseases and cancer [13:15];

  • How the liver metabolizes nutrients and what happens in the presence of excess calories or alcohol [24:45];

  • Methods of diagnosing liver disease and how insights guide treatment and management strategies [33:30];

  • The poisonous nature of ethanol to the liver [40:30];

  • Varied responses to alcohol, damaging effects of alcohol beyond the liver, and the process of advising patients on their alcohol consumption [47:15];

  • Understanding liver enzymes AST and ALT—interpreting levels, lifestyle factors that affect them, and diagnostic approaches [58:30];

  • Interpreting liver function tests for fatty liver disease, and the challenges of diagnosing liver pathologies, particularly in children versus adults [1:13:15];

  • Comprehensive liver health assessments via imaging and various diagnostic to

Episode description

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter’s Weekly Newsletter

Julia Wattacheril is a physician scientist and director of the Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) program at Columbia University Irving Medical Center. In this episode, Julia delves deep into the complex world of liver health, beginning with a foundational overview of liver physiology. She provides an in-depth look at how alcohol impacts liver function, breaking down the metabolism of ethanol and its detrimental effects. Julia then shifts the focus to understanding liver function tests and optimal enzyme levels, providing a detailed explanation of AST and ALT and elucidating why fluctuations in these levels may or may not be concerning. She provides a primer on the four major stages of liver disease, discussing risk and emphasizing the importance of early diagnosis. Julia highlights the role of liver disease in increasing the risk of cancer and cardiovascular disease and covers in detail the various strategies for diagnosing, treating, and preventing the progression of liver disease.

We discuss:

  • Julia’s training, the importance of liver health, and the challenges and innovations of hepatology [3:15];

  • The complex and crucial functionality of the liver, its four most essential functions, and more [8:45];

  • Liver injuries: historical and evolving understanding of causal factors, and the progression to liver diseases and cancer [13:15];

  • How the liver metabolizes nutrients and what happens in the presence of excess calories or alcohol [24:45];

  • Methods of diagnosing liver disease and how insights guide treatment and management strategies [33:30];

  • The poisonous nature of ethanol to the liver [40:30];

  • Varied responses to alcohol, damaging effects of alcohol beyond the liver, and the process of advising patients on their alcohol consumption [47:15];

  • Understanding liver enzymes AST and ALT—interpreting levels, lifestyle factors that affect them, and diagnostic approaches [58:30];

  • Interpreting liver function tests for fatty liver disease, and the challenges of diagnosing liver pathologies, particularly in children versus adults [1:13:15];

  • Comprehensive liver health assessments via imaging and various diagnostic to

Mindsip insights from this episode:

Drink up to three cups of black coffee daily for liver health

Up to three cups of black coffee per day has been shown in multiple studies to have beneficial, anti-fibrotic effects on the liver for various liver diseases.

Recognize Hepatitis B as a cancer risk without cirrhosis

Unlike other liver diseases, Hepatitis B is an outlier that can lead to liver cancer even before the liver progresses to advanced fibrosis or cirrhosis.

Don't rely on standard ultrasound to detect fatty liver

A standard ultrasound is not sensitive enough to detect fatty liver until it reaches about 30% fat, meaning a negative result doesn't rule out the condition.

Utilize FibroScan for accurate assessment of alcohol-induced fatty liver

A bedside imaging technique like a FibroScan is more sensitive for picking up on alcohol-induced fatty liver than blood tests for liver enzymes like AST and ALT.

Utilize PEth test to monitor alcohol consumption

The phosphatidyl ethanol (PEth) test is a blood test, similar to an A1C for glucose, that can measure moderate to severe alcohol consumption over the previous one to two weeks.

Aim for liver enzymes below optimal level of 30

An optimal level for liver enzymes AST and ALT is generally under 30, which is lower than the standard lab reference ranges that have drifted up with population health.

Prioritize heart health to combat early fatty liver risks

For the average person with early-stage metabolic fatty liver disease (MASLD), the risk of cardiovascular events and malignancy is much higher and more immediate than the risk of liver failure.

Utilize Resmetirom to treat metabolic dysfunction-associated steatotic liver disease

A new thyroid hormone receptor agonist drug called Resmetirom has shown promising results in a Phase 3 trial for treating metabolic dysfunction-associated steatotic liver disease (MASLD).

Reverse early-stage cirrhosis with new evidence

Contrary to traditional teaching, there is now evidence that even early cirrhosis, which is stage four scarring of the liver, can be reversible.

DOWNLOAD THE APP

Unlock the wisdom of longevity

DOWNLOAD THE APP

Unlock the wisdom of longevity

DOWNLOAD THE APP

Unlock the wisdom of longevity

Unlock the wisdom of longevity

© Mindsip 2025 – Made with ❤ in Vilnius

Unlock the wisdom of longevity

© Mindsip 2025 – Made with ❤ in Vilnius